These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 38270832)

  • 1. ASO Author Reflections: Fathoming the Dilemma of the Optimal Time to Surgery for Patients with Resectable Esophageal Cancer After Neoadjuvant Chemoradiotherapy.
    Li J; Wang Q
    Ann Surg Oncol; 2024 Jun; 31(6):3852-3853. PubMed ID: 38270832
    [No Abstract]   [Full Text] [Related]  

  • 2. ASO Author Reflections: Neoadjuvant Chemotherapy versus Definitive Chemoradiation Therapy for Locally Advanced Cervical Esophageal Cancer: A Retrospective Study.
    Kubo Y; Kato K; Daiko H
    Ann Surg Oncol; 2024 Aug; 31(8):5308-5309. PubMed ID: 38802715
    [No Abstract]   [Full Text] [Related]  

  • 3. Optimal Time-to-Surgery Recommendations Based on Primary Tumor Volume Regression for Patients with Resectable Esophageal Cancer after Neoadjuvant Chemoradiotherapy: A Retrospective Study.
    Li J; Zhou X; Liu Y; Zhu J; Wan G; Wang Y; Leng X; Han Y; Peng L; Wu L; Wang Q
    Ann Surg Oncol; 2024 Jun; 31(6):3803-3812. PubMed ID: 38280959
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CMISG1701: a multicenter prospective randomized phase III clinical trial comparing neoadjuvant chemoradiotherapy to neoadjuvant chemotherapy followed by minimally invasive esophagectomy in patients with locally advanced resectable esophageal squamous cell carcinoma (cT
    Tang H; Tan L; Shen Y; Wang H; Lin M; Feng M; Xu S; Guo W; Qian C; Liu T; Zeng Z; Hou Y; Yu Z; Jiang H; Li Z; Chen C; Lian C; Du M; Li H; Xie D; Yin J; Zhao N; Wang Q
    BMC Cancer; 2017 Jun; 17(1):450. PubMed ID: 28659128
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Is esophagectomy necessary for esophageal cancer patients with complete response after neoadjuvant chemoradiotherapy].
    Fu J; Tan Z
    Zhonghua Wei Chang Wai Ke Za Zhi; 2018 Sep; 21(9):983-986. PubMed ID: 30269316
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ASO Author Reflections: Intensified Neoadjuvant Chemoradiotherapy Followed by Esophagectomy in Esophageal Cancer.
    Boers J; de Groot JWB
    Ann Surg Oncol; 2020 May; 27(5):1529. PubMed ID: 32112209
    [No Abstract]   [Full Text] [Related]  

  • 7. ASO Author Reflections: Evaluation of Tumor Regression After Neoadjuvant Chemoradiotherapy in Esophageal Carcinoma-How to Do It?
    Takeda FR; Tustumi F; Cecconello I
    Ann Surg Oncol; 2020 Apr; 27(4):1248-1249. PubMed ID: 31673941
    [No Abstract]   [Full Text] [Related]  

  • 8. ASO Author Reflections: Preservation of the Thoracic Duct is Feasible for Esophageal Squamous Cell Carcinoma Patients Treated with Esophagectomy After Neoadjuvant Chemoradiotherapy.
    Oshikiri T; Numasaki H; Oguma J; Toh Y; Watanabe M; Muto M; Kakeji Y; Doki Y
    Ann Surg Oncol; 2023 May; 30(5):2699-2700. PubMed ID: 36629993
    [No Abstract]   [Full Text] [Related]  

  • 9. ASO Author Reflections: Comparison of Aggressive Planned Salvage Surgery versus Neoadjuvant Chemoradiotherapy Plus Surgery for Borderline Resectable T4 Squamous Cell Carcinoma.
    Shiraishi O
    Ann Surg Oncol; 2021 Oct; 28(11):6376-6377. PubMed ID: 33830358
    [No Abstract]   [Full Text] [Related]  

  • 10. Neoadjuvant therapy for advanced esophageal cancer: the impact on surgical management.
    Ikebe M; Morita M; Yamamoto M; Toh Y
    Gen Thorac Cardiovasc Surg; 2016 Jul; 64(7):386-94. PubMed ID: 27165288
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ASO Author Reflections: Timing of Oesophagectomy After Neoadjuvant Chemoradiotherapy for Locally Advanced Oesophageal Cancer.
    Xiao X; Cheng C; Cheng L; Yuan Y
    Ann Surg Oncol; 2023 Feb; 30(2):897-898. PubMed ID: 36322273
    [No Abstract]   [Full Text] [Related]  

  • 12. Comparison between surgery and definitive chemoradiotherapy for patients with resectable esophageal squamous cell carcinoma: a propensity score analysis.
    Nomura M; Oze I; Kodaira T; Abe T; Komori A; Narita Y; Masuishi T; Taniguchi H; Kadowaki S; Ura T; Andoh M; Tachibana H; Uemura N; Tajika M; Niwa Y; Muto M; Muro K
    Int J Clin Oncol; 2016 Oct; 21(5):890-898. PubMed ID: 26980212
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimal Use of Combined Modality Therapy in the Treatment of Esophageal Cancer.
    Shaikh T; Meyer JE; Horwitz EM
    Surg Oncol Clin N Am; 2017 Jul; 26(3):405-429. PubMed ID: 28576180
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increasing the interval between neoadjuvant chemoradiotherapy and surgery in esophageal cancer: a meta-analysis of published studies.
    Lin G; Han SY; Xu YP; Mao WM
    Dis Esophagus; 2016 Nov; 29(8):1107-1114. PubMed ID: 26542065
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ASO Author Reflections: Neoadjuvant Chemotherapy or Neoadjuvant Chemoradiotherapy for Patients with Esophageal Squamous Cell Carcinoma: Real-World Data Comparison from a Japanese Nationwide Study.
    Okamura A; Watanabe M; Okui J; Matsuda S; Takemura R; Kawakubo H; Takeuchi H; Muto M; Kakeji Y; Kitagawa Y; Doki Y
    Ann Surg Oncol; 2023 Sep; 30(9):5895-5896. PubMed ID: 37266806
    [No Abstract]   [Full Text] [Related]  

  • 16. Analysis of patients scheduled for neoadjuvant therapy followed by surgery for esophageal cancer, who never made it to esophagectomy.
    Depypere L; Thomas M; Moons J; Coosemans W; Lerut T; Prenen H; Haustermans K; Van Veer H; Nafteux P
    World J Surg Oncol; 2019 May; 17(1):89. PubMed ID: 31133018
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Definitive Chemoradiotherapy Compared to Neoadjuvant Chemoradiotherapy With Esophagectomy for Locoregional Esophageal Cancer: National Population-based Cohort Study.
    Kamarajah SK; Phillips AW; Hanna GB; Low D; Markar SR
    Ann Surg; 2022 Mar; 275(3):526-533. PubMed ID: 32865948
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ASO Author Reflections: Association Between Preoperative Coagulation Status and Prognosis in Patients Undergoing Subtotal Esophagectomy for Esophageal Squamous Cell Carcinoma After Neoadjuvant Treatment.
    Sugiyama F; Kanda M; Kodera Y
    Ann Surg Oncol; 2024 May; 31(5):3473-3474. PubMed ID: 38261127
    [No Abstract]   [Full Text] [Related]  

  • 19. ASO Author Reflections: Safety and Feasibility of Robot-Assisted Minimally Invasive Esophagectomy (RAMIE) with Three-Field Lymphadenectomy and Neoadjuvant Chemoradiotherapy in Patients with Resectable Esophageal Cancer and Cervical Lymph Node Metastasis.
    Weijs TJ; van der Horst S; van Hillegersberg R
    Ann Surg Oncol; 2023 May; 30(5):2753-2754. PubMed ID: 36735084
    [No Abstract]   [Full Text] [Related]  

  • 20. Planned Esophagectomy after Neoadjuvant Hyperthermo-Chemoradiotherapy using Weekly Low-Dose Docetaxel and Hyperthermia for Advanced Esophageal Carcinomas.
    Nakajima M; Kato H; Sakai M; Sano A; Miyazaki T; Sohda M; Inose T; Tanaka N; Suzuki S; Masuda N; Fukuchi M; Kuwano H
    Hepatogastroenterology; 2015 Jun; 62(140):887-91. PubMed ID: 26902022
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.